Showing results (191-200 of 1,860) with videos related to
Sort By:
Pageof 186
ACS Medicinal Chemistry Letters|July 16, 2025
Synthesis of Novel Substituted N‑Heterocycles and Their Use of Selective Poly(ADP-ribose) Polymerase 1 (PARP1) InhibitorsXin Zhou, Steven H LiangACS Medicinal Chemistry Letters|July 16, 2025
Selective Modulation of the GluN2B/C/D Containing N‑Methyl‑d‑Aspartate Receptors: A New Frontier in Targeted NeurotherapeuticsYinlong Li, Steven H LiangACS Medicinal Chemistry Letters|October 15, 2025
Development of Novel Compounds and Methods for Treatment of PARPs Mediated DiseaseXin Zhou, Steven H LiangACS Medicinal Chemistry Letters|May 14, 2025
PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational MedicineTaoqian Zhao, Steven H LiangACS Medicinal Chemistry Letters|May 14, 2025
Novel Nonpeptide as Oxytocin Receptor AgonistYinlong Li, Steven H LiangACS Medicinal Chemistry Letters|August 20, 2025
Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer TreatmentXin Zhou, Steven H LiangACS Medicinal Chemistry Letters|February 18, 2026
Novel Pyridopyrazine Derivatives as Inverse Agonists of the G Protein-Coupled Receptor 6Yinlong Li, Steven H LiangACS Medicinal Chemistry Letters|March 19, 2025
Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS DisordersSiyan Feng, Steven H LiangACS Medicinal Chemistry Letters|April 16, 2025
Novel Pyrazolo[1,5-a]pyrimidine-3,5-diamines as nSMase2 InhibitorsJian Rong, Steven H LiangACS Medicinal Chemistry Letters|March 18, 2026
Novel Macrocyclic Compounds Targeting KRAS Mutations for Cancer TreatmentLingxin Meng, Steven H LiangPageof 186